Risk estimation for the next generation of prevention programmes for cervical cancer

The Lancet Oncology

Volumn 10, Issue 11, 2009, Pages 1022-1023

  Katki, Hormuzd A ^a   Wacholder, Sholom ^a   Solomon, Diane ^a   Castle, Philip E ^a   Schiffman, Mark ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

CANCER GRADING; CANCER RISK; CANCER SCREENING; COLPOSCOPY; DNA DETERMINATION; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; INDIVIDUALIZATION; LETTER; MEDICAL DECISION MAKING; PATIENT REFERRAL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK MANAGEMENT; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADULT; ALGORITHMS; CLINICAL PROTOCOLS; DECISION SUPPORT TECHNIQUES; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MASS SCREENING; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PREVENTIVE HEALTH SERVICES; RISK ASSESSMENT; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; WOMEN'S HEALTH SERVICES;

EID: 71249085643     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70253-0     Document Type: Letter

References (11)

1. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., and Wacholder S. Human papillomavirus and cervical cancer. Lancet 370 (2007) 890-907
2. Wright T.C., Massad L.S., Dunton C.J., et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 197 (2007) 346-355
3. Wright T.C., Massad L.S., Dunton C.J., et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 197 (2007) 340-345
4. Bulkmans N.W.J., Berkhof J., and Rozendaal L. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370 (2007) 1764-1772
5. Qiao Y., Sellors J.W., Eder P.S., et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 9 (2008) 929-936
6. Sankaranarayanan R., Nene B.M., Shastri S.S., et al. HPV screening for cervical cancer in rural India. N Engl J Med 360 (2009) 1385-1394
7. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
8. Paavonen J., Naud P., Salmerón J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374 (2009) 301-314
9. Cuschieri K., and Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 17 (2008) 2536-2545
10. Gravitt P.E., Coutlée F., Iftner T., et al. New technologies in cervical cancer screening. Vaccine 26 suppl 10 (2008) K42-K52
11. Castle P.E., Sideri M., Jeronimo J., Solomon D., and Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 197 (2007) 356.e1-356.e6